Loading...
•
Dec 31, 2021
Allovir Q4 2021 Earnings Report
Reported full-year financial results and provided 2022 outlook.
Key Takeaways
AlloVir reported its full-year 2021 financial results, highlighting advancements in its clinical development programs, including three Phase 3 registrational studies for posoleucel. The company also reported a strong cash position with $248.1 million at year-end.
Three ongoing Phase 3 registrational studies of posoleucel are expected in 2022, targeting treatment and prevention indications.
Enrollment expanded in Phase 2 proof-of-concept study of posoleucel for BK viremia in kidney transplant recipients.
Two additional virus-specific T cell therapies are advancing: ALVR106 for respiratory viral infections and ALVR107 for hepatitis B cure.
Cash and cash equivalents totaled $248.1 million at year-end 2021.
Forward Guidance
AlloVir anticipates key milestones in 2022, including the advancement of posoleucel through Phase 3 trials and the continued development of its VST therapies.
Positive Outlook
- Global enrollment is ongoing in registrational studies of posoleucel for the treatment of virus-associated HC.
- Global enrollment is ongoing in registrational studies of posoleucel for the treatment of AdV infections.
- A Phase 3 registrational trial for multi-virus prevention is expected to initiate in the first half of this year.
- Initial data from the ongoing posoleucel POC study for BKV treatment in KT recipients expected in the first half of 2022.
- Preclinical and IND-enabling studies of ALVR107 to treat and cure hepatitis B will be completed in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...